Reduction of [11C](+)3-MPB Binding in Brain of Chronic Fatigue Syndrome with Serum Autoantibody against Muscarinic Cholinergic Receptor

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Yamamoto, Shigeyuki ^a,b   Ouchi, Yasuomi ^c   Nakatsuka, Daisaku ^a   Tahara, Tsuyoshi ^d   Mizuno, Kei ^d   Tajima, Seiki ^a   Onoe, Hirotaka ^d   Yoshikawa, Etsuji ^b   Tsukada, Hideo ^b   Iwase, Masao ^e   Yamaguti, Kouzi ^a   Kuratsune, Hirohiko ^f   Watanabe, Yasuyoshi ^a,d  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Central Research Laboratory   (Japan)

^c HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d RIKEN   (Japan)

^e OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^f KANSAI UNIVERSITY OF WELFARE SCIENCES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINESTERASE; AUTOANTIBODY; CARBON 11; MEPENZOLATE; MUSCARINIC RECEPTOR; 3 (N MALEIMIDOPROPIONYL)BIOCYTIN; 3-(N-MALEIMIDOPROPIONYL)BIOCYTIN; CARBON; DIAGNOSTIC AGENT; DRUG DERIVATIVE; LYSINE; MALEIMIDE DERIVATIVE;

ADULT; AMYGDALOID NUCLEUS; ANTERIOR CINGULATE; ANTIBODY BLOOD LEVEL; ARTICLE; BRAIN FUNCTION; BRAIN RADIOGRAPHY; BRAIN REGION; BRAIN STEM; CHOLINERGIC SYSTEM; CHRONIC FATIGUE SYNDROME; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COGNITION; CONTROLLED STUDY; CORPUS STRIATUM; ENZYME ACTIVITY; FEMALE; HUMAN; MALE; NEUROIMAGING; NEUROPSYCHOLOGICAL TEST; OCCIPITAL CORTEX; ORBITAL CORTEX; PARIETAL CORTEX; POSITRON EMISSION TOMOGRAPHY; RECEPTOR BINDING; REDUCTION KINETICS; TEMPORAL CORTEX; THALAMUS; BLOOD; BRAIN MAPPING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; IMMUNOLOGY; METABOLISM; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY;

ACETYLCHOLINESTERASE; ADULT; AUTOANTIBODIES; BRAIN MAPPING; CARBON RADIOISOTOPES; FATIGUE SYNDROME, CHRONIC; FEMALE; HUMANS; LYSINE; MAGNETIC RESONANCE IMAGING; MALE; MALEIMIDES; RECEPTORS, MUSCARINIC; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 84871174398     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0051515     Document Type: Article

References (67)

1. Collerton D, (1986) Cholinergic function and intellectual decline in Alzheimer's disease. Neuroscience 19: 1-28.
2. Hasselmo ME, (2006) The role of acetylcholine in learning and memory. Curr Opin Neurobiol 16: 710-715.
3. Sellin AK, Shad M, Tamminga C, (2008) Muscarinic agonists for the treatment of cognition in schizophrenia. CNS Spectr 13: 985-996.
4. Kobayashi Y, Inoue Y, Yamamoto M, Isa T, Aizawa H, (2002) Contribution of pedunculopontine tegmental nucleus neurons to performance of visually guided saccade tasks in monkeys. J Neurophysiol 88: 715-731.
5. Matsumura M, Watanabe K, Ohye C, (1997) Single-unit activity in the primate nucleus tegmenti pedunculopontinus related to voluntary arm movement. Neurosci Res 28: 155-165.
6. Steriade M, (1992) Basic mechanisms of sleep generation. Neurology 42: 9-17.
7. Höhmann C, Antuono P, Coyle JT (1998) Basal forebrain cholinergic neurons and Alzheimer's disease. In: Iversen LL, Iversen SD, Snyder SD, editors. Psychopharmacology of the aging nervous system. New York: Plenum. 69-106.
8. Perry EK, (1986) The cholinergic hypothesis-ten years on. Br Med Bull 42: 63-69.
9. Terry AV Jr, Buccafusco JJ, (2003) The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: recent challenges and their implications for novel drug development. J Pharmacol Exp Ther 306: 821-827.
10. Reinikainen KJ, Riekkinen PJ, Halonen T, Laakso M, (1987) Decreased muscarinic receptor binding in cerebral cortex and hippocampus in Alzheimer's disease. Life Sci 41: 453-461.
11. Rinne JO, Laakso K, Lönnberg P, Mölsä P, Paljärvi L, et al. (1985) Brain muscarinic receptors in senile dementia. Brain Res 336: 19-25.
12. Enna SJ, Bird ED, Bennett JP Jr, Bylund DB, Yamamura HI, et al. (1976) Huntington's chorea. Changes in neurotransmitter receptors in the brain. N Engl J Med 294: 1305-1309.
13. Lange KW, Javoy-Agid F, Agid Y, Jenner P, Marsden CD, (1992) Brain muscarinic cholinergic receptors in Huntington's disease. J Neurol 239: 103-104.
14. Wastek GJ, Yamamura HI, (1978) Biochemical characterization of the muscarinic cholinergic receptor in human brain: alterations in Huntington's disease. Mol Pharmacol 14: 768-780.
15. Ahlskog JE, Richelson E, Nelson A, Kelly PJ, Okazaki H, et al. (1991) Reduced D2 dopamine and muscarinic cholinergic receptor densities in caudate specimens from fluctuating parkinsonian patients. Ann Neurol 30: 185-191.
16. Crook JM, Tomaskovic-Crook E, Copolov DL, Dean B, (2000) Decreased muscarinic receptor binding in subjects with schizophrenia: a study of the human hippocampal formation. Biol Psychiatry 48: 381-388.
17. Dean B, McLeod M, Keriakous D, McKenzie J, Scarr E, (2002) Decreased muscarinic1 receptors in the dorsolateral prefrontal cortex of subjects with schizophrenia. Mol Psychiatry 7: 1083-1091.
18. Zavitsanou K, Katsifis A, Mattner F, Huang XF, (2004) Investigation of m1/m4 muscarinic receptors in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression disorder. Neuropsychopharmacology 29: 619-625.
19. Kubo T, Fukuda K, Mikami A, Maeda A, Takahashi H, et al. (1986) Cloning, sequencing and expression of complementary DNA encoding the muscarinic acetylcholine receptor. Nature 323: 411-416.
20. Bymaster FP, Felder C, Ahmed S, McKinzie D, (2002) Muscarinic receptors as a target for drugs treating schizophrenia. Curr Drug Targets CNS Neurol Disord 1: 163-181.
21. Diamond B, Huerta PT, Mina-Osorio P, Kowal C, Volpe BT, (2009) Losing your nerves? Maybe it's the antibodies. Nat Rev Immunol 9: 449-456.
22. Morshed SA, Parveen S, Leckman JF, Mercadante MT, Bittencourt Kiss MH, et al. (2001) Antibodies against neural, nuclear, cytoskeletal, and streptococcal epitopes in children and adults with Tourette's syndrome, Sydenham's chorea, and autoimmune disorders. Biol Psychiatry 50: 566-577.
23. Perlmutter SJ, Leitman SF, Garvey MA, Hamburger S, Feldman E, et al. (1999) Therapeutic plasma exchange and intravenous immunoglobulin for obsessive-compulsive disorder and tic disorders in childhood. Lancet 354: 1153-1158.
24. Diamond B, Kowal C, Huerta PT, Aranow C, Mackay M, et al. (2006) Immunity and acquired alterations in cognition and emotion: lessons from SLE. Adv Immunol 89: 289-320.
25. Afari N, Buchwald D, (2003) Chronic fatigue syndrome: a review. Am J Psychiatry 160: 221-236.
26. Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, et al. (1994) The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann Intern Med 121: 953-959.
27. Lyall M, Peakman M, Wessely S, (2003) A systematic review and critical evaluation of the immunology of chronic fatigue syndrome. J Psychosom Res 55: 79-90.
28. Raison CL, Lin JM, Reeves WC, (2009) Association of peripheral inflammatory markers with chronic fatigue in a population-based sample. Brain Behav Immun 23: 327-337.
29. Hatcher S, House A, (2003) Life events, difficulties and dilemmas in the onset of chronic fatigue syndrome: a case-control study. Psychol Med 33: 1185-1192.
30. Tanaka M, Watanabe Y, (2010) A new hypothesis of chronic fatigue syndrome: co-conditioning theory. Med Hypotheses 75: 244-249.
31. Argaw AT, Zhang Y, Snyder BJ, Zhao ML, Kopp N, et al. (2006) IL-1beta regulates blood-brain barrier permeability via reactivation of the hypoxia-angiogenesis program. J Immunol 177: 5574-5584.
32. Banks WA, (2005) Blood-brain barrier transport of cytokines: a mechanism for neuropathology. Curr Pharm Des 11: 973-984.
33. Bauer B, Hartz AM, Miller DS, (2007) Tumor necrosis factor alpha and endothelin-1 increase P glycoprotein expression and transport activity at the blood-brain barrier. Mol Pharmacol 71: 667-675.
34. Paul R, Koedel U, Winkler F, Kieseier BC, Fontana A, et al. (2003) Lack of IL-6 augments inflammatory response but decreases vascular permeability in bacterial meningitis. Brain 126: 1873-1882.
35. Schwarz MJ, Ackenheil M, Riedel M, Müller N, (1998) Blood-cerebrospinal fluid barrier impairment as indicator for an immune process in schizophrenia. Neurosci Lett 253: 201-203.
36. Kuang F, Wang BR, Zhang P, Fei LL, Jia Y, et al. (2004) Extravasation of blood-borne immunoglobulin G through blood-brain barrier during adrenaline-induced transient hypertension in the rat. Int J Neurosci 114: 575-791.
37. Tanaka S, Kuratsune H, Hidaka Y, Hakariya Y, Tatsumi KI, et al. (2003) Autoantibodies against muscarinic cholinergic receptor in chronic fatigue syndrome. Int J Mol Med 12: 225-230.
38. Tsukada H, Takahashi K, Miura S, Nishiyama S, Kakiuchi T, et al. (2001) Evaluation of novel PET ligands (+)N-[11C]methyl-3-piperidyl benzilate ([11C](+)3-MPB) and its stereoisomer [11C](-)3-MPB for muscarinic cholinergic receptors in the conscious monkey brain: a PET study in comparison with [11C]4-MPB. Synapse 39: 182-192.
39. Irie T, Fukushi K, Namba H, Iyo M, Tamagami H, et al. (1996) Brain acetylcholinesterase activity: validation of a PET tracer in a rat model of Alzheimer's disease. J Nucl Med 37: 649-655.
40. Namba H, Iyo M, Shinotoh H, Nagatsuka S, Fukushi K, et al. (1998) Preserved acetylcholinesterase activity in aged cerebral cortex. Lancet 351: 881-882.
41. Namba H, Iyo M, Fukushi K, Shinotoh H, Nagatsuka S, et al. (1999) Human cerebral acetylcholinesterase activity measured with positron emission tomography: procedure, normal values and effect of age. Eur J Nucl Med 26: 135-143.
42. Yamamoto S, Ouchi Y, Onoe H, Yoshikawa E, Tsukada H, et al. (2004) Reduction of serotonin transporters of patients with chronic fatigue syndrome. Neuroreport 15: 2571-2574.
43. Matsuoka K, Uno M, Kasai K, Koyama K, Kim Y, (2006) Estimation of premorbid IQ in individuals with Alzheimer's disease using Japanese ideographic script (Kanji) compound words: Japanese version of National Adult Reading Test. Psychiatry Clin Neurosci 60: 332-339.
44. Tsuchiya H, Yamaguchi S, Kobayashi S, (2000) Impaired novelty detection and frontal lobe dysfunction in Parkinson's disease. Neuropsychologia 38: 645-654.
45. Reitan RM (1956) Trail Making Test: Manual for Administration, Scoring and Interpretation, Indianapolis.
46. Horikoshi T, Matsue K, Takahashi T, Ishii H, Yamada K, et al. (2004) Objective determination of fatigue development following sun exposure using Advanced Trail Making Test. Int J Cosmet Sci 26: 9-17.
47. Tajima S, Yamamoto S, Tanaka M, Kataoka Y, Iwase M, et al. (2010) Medial orbitofrontal cortex is associated with fatigue sensation. Neurology Research International doi: 10.1155/2010/671421.
48. Spreen O, Strauss E (1998) A compendium of neuropsychological tests - Administration, Norms and Commentary. Oxford University Press, New York.
49. Wechsler D (1987) Wechsler Memory Scale Revised. The Psychological Corporation. Harcourt Brace Jovanovich, Inc.
50. Takahashi K, (1998) Development and clinical application of novel C-11-labeled ligand for imaging cholinergic muscarinic receptors in the brain with positron emission tomography. Thesis Tohoku Univ 3041: 1-54 (in Japanese).
51. Yamamoto S, Ohba H, Nishiyama S, Takahashi K, Tsukada H, (2010) Validation of reference tissue model of PET ligand [11C](+)3-MPB for the muscarinic cholinergic receptor in the living brain of conscious monkey. Synapse 65: 548-551.
52. Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, et al. (1996) Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 16: 834-840.
53. Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, et al. (2007) Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 27: 1533-1539.
54. Buck A, Gucker PM, Schönbächler RD, Arigoni M, Kneifel S, et al. (2000) Evaluation of serotonergic transporters using PET and [11C](+)McN-5652: assessment of methods. J Cereb Blood Flow Metab 20: 253-262.
55. Eggers C, Szelies B, Bauer B, Wienhard K, Schröder H, et al. (2007) Imaging of acetylcholine esterase activity in brainstem nuclei involved in regulation of sleep and wakefulness. Eur J Neurol 14: 690-693.
56. Ota T, Shinotoh H, Fukushi K, Nagatsuka S, Namba H, et al. (2004) A simple method for the detection of abnormal brain regions in Alzheimer's disease patients using [11C]MP4A: comparison with [123I]IMP SPECT. Ann Nucl Med 18: 187-193.
57. Axelsson R, Martensson E, Alling C, (1982) Impairment of the blood-brain barrier as an aetiological factor in paranoid psychosis. Br J Psychiatry 141: 273-281.
58. Noy S, Achiron A, Laor N, (1994) Schizophrenia and autoimmunity-a possible etiological mechanism? Neuropsychobiology 30: 157-159.
59. Levy JA, (1994) Viral studies of chronic fatigue syndrome. Clin Infect Dis 18: S117-120.
60. Nishiyama S, Tsukada H, Sato K, Kakiuchi T, Ohba H, et al. (2001) Evaluation of PET ligands (+)N-[(11)C]ethyl-3-piperidyl benzilate and (+)N-[(11)C]propyl-3-piperidyl benzilate for muscarinic cholinergic receptors: a PET study with microdialysis in comparison with (+)N-[(11)C]methyl-3-piperidyl benzilate in the conscious monkey brain. Synapse 40: 159-169.
61. Borda T, Perez Rivera R, Joensen L, Gomez RM, Sterin-Borda L, (2002) Antibodies against cerebral M1 cholinergic muscarinic receptor from schizophrenic patients: molecular interaction. J Immunol 168: 3667-3674.
62. Ganzinelli S, Borda T, Sterin-Borda L, (2006) Regulation of m1 muscarinic receptors and nNOS mRNA levels by autoantibodies from schizophrenic patients. Neuropharmacology 50: 362-371.
63. Flynn DD, Ferrari-DiLeo G, Mash DC, Levey AI, (1995) Differential regulation of molecular subtypes of muscarinic receptors in Alzheimer's disease. J Neurochem 64: 1888-1891.
64. Yamamoto S, Maruyama S, Ito Y, Kawamata M, Nishiyama S, et al. (2011) Effect of oxybutynin and imidafenacin on central muscarinic receptor occupancy and cognitive function: a monkey PET study with [(11)C](+)3-MPB. Neuroimage 58: 1-9.
65. Yamamoto S, Nishiyama S, Kawamata M, Ohba H, Wakuda T, et al. (2011) Muscarinic receptor occupancy and cognitive impairment: a PET study with [11C](+)3-MPB and scopolamine in conscious monkeys. Neuropsychopharmacology 36: 1455-1465.
66. Reina S, Sterin-Borda L, Orman B, Borda E, (2004) Autoantibodies against cerebral muscarinic cholinoceptors in Sjögren syndrome: functional and pathological implications. J Neuroimmunol 150: 107-115.
67. Tanaka S, Matsunaga H, Kimura M, Tatsumi K, Hidaka Y, et al. (2003) Autoantibodies against four kinds of neurotransmitter receptors in psychiatric disorders. J Neuroimmunol 141: 155-164.